PF-07329640 + bevacizumab

PF-07329640 + bevacizumab is a combination investigational regimen being evaluated in clinical trials for the treatment of advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC) and microsatellite stable (MSS) colorectal cancer. PF-07329640 is an experimental biologic that targets the lymphotoxin beta receptor (LTβR), functioning as an antagonist (αLTβR), and is being tested for its immunomodulatory and potential antitumor activities. Bevacizumab is an approved monoclonal antibody against vascular endothelial growth factor A (VEGF-A), used to inhibit angiogenesis and tumor vascularization. The combination is administered intravenously in cycle-based regimens and is currently in early clinical development. Pfizer is the developer and lead sponsor for the combination's clinical program[1][2].